Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia

被引:9
作者
Costa, D
Carrió, A
Madrigal, I
Arias, A
Valera, A
Colomer, D
Aguilar, JL
Teixido, M
Camós, M
Cervantes, F
Campo, E
机构
[1] Hosp Clin Barcelona, Hematopathol Unit, Barcelona 08036, Catalonia, Spain
[2] Hosp Clin Barcelona, Genet Serv, Barcelona 08036, Catalonia, Spain
[3] Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Catalonia, Spain
[4] Hosp Arnau Vilanova, Lleida, Catalonia, Spain
关键词
D O I
10.1016/j.cancergencyto.2005.08.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 121q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 17 条
[11]   Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia [J].
Quintas-Cardama, A ;
Kantarjian, H ;
Talpaz, M ;
O'Brien, S ;
Garcia-Manero, G ;
Verstovsek, S ;
Rios, MB ;
Hayes, K ;
Glassman, A ;
Bekele, BN ;
Zhou, M ;
Cortes, J .
BLOOD, 2005, 105 (06) :2281-2286
[12]   A FISH study of variant Philadelphia rearrangements [J].
Reddy, KS ;
Sulcova, V .
CANCER GENETICS AND CYTOGENETICS, 2000, 118 (02) :121-131
[13]   Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia [J].
Reid, AG ;
Huntly, BJP ;
Grace, C ;
Green, AR ;
Nacheva, EP .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) :419-427
[14]   Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia [J].
Sinclair, PB ;
Nacheva, EP ;
Leversha, M ;
Telford, N ;
Chang, J ;
Reid, A ;
Bench, A ;
Champion, K ;
Huntly, B ;
Green, AR .
BLOOD, 2000, 95 (03) :738-744
[15]   Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients [J].
Storlazzi, CT ;
Specchia, G ;
Anelli, L ;
Albano, F ;
Pastore, D ;
Zagaria, A ;
Rocchi, M ;
Liso, V .
GENES CHROMOSOMES & CANCER, 2002, 35 (03) :271-276
[16]   Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive [J].
Yehuda, O ;
Abeliovich, D ;
Ben-Neriah, S ;
Sverdlin, I ;
Cohen, R ;
Varadi, G ;
Orr, R ;
Ashkenazi, YJ ;
Heyd, J ;
Lugassy, G ;
Ben Yehuda, D .
CANCER GENETICS AND CYTOGENETICS, 1999, 114 (02) :100-107
[17]   Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia [J].
Yoong, Y ;
VanDeWalker, TJ ;
Carlson, RO ;
Dewald, GW ;
Tefferi, A .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (02) :124-127